Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9438364 | 1.00 | CYP3A4 (0.73) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL5161822 | 1.00 | CYP3A4 (0.73) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL8394379 | 1.00 | CYP3A4 (0.73) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL4734129 | 0.98 | CYP3A4 (0.77) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL15732744 | 0.96 | CYP3A4 (0.69) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL15738975 | 0.96 | CYP3A4 (0.69) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL28943055 | 0.94 | CYP3A4 (0.71) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL28840278 | 0.93 | CYP3A4 (0.86) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL15732821 | 0.93 | CYP3A4 (0.86) | CYP3A4HTTTLR2DNM1MEN1 | |
| SCHEMBL5475375 | 0.88 | CYP3A4 (0.55) | CYP3A4HTTMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442242-B2 | Phase change inks containing specific colorants | XEROX CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7381255-B2 | Phase change inks | XEROX CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-7294730-B2 | Colorant compounds | XEROX CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070123701-A1 | Colorant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120918-A1 | Phase change inks | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120915-A1 | Phase change inks containing specific colorants | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-5298038-A | Cleaning coke from injection nozzle | KAO CORPORATION (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0353713-B1 | Use of an additive for fuel | KAO CORP (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0353713-A1 | Use of an additive for fuel | Kao Corporation (JP) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123701-A1 | Colorant compounds | RB1, CCNE2, NQO1 | CYP3A4 435/4885HTT 2687/4885TLR2 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.